| Title |
Role of pharmacogenomics in the treatment of tuberculosis: a review
|
|---|---|
| Published in |
Pharmacogenomics and Personalized Medicine, September 2012
|
| DOI | 10.2147/pgpm.s15454 |
| Pubmed ID | |
| Authors |
Geetha Ramachandran, Soumya Swaminathan |
| Abstract |
Tuberculosis is one of the major public health problems worldwide. Modern antituberculous treatment can cure most patients; cure rates > 95% are achieved with standard short-course chemotherapy regimens containing isoniazid, rifampicin, pyrazinamide, and ethambutol among patients with drug-susceptible strains of tuberculosis; however, a small proportion do not respond to treatment or develop serious adverse events. Pharmacogenomic studies of drugs used in the treatment of tuberculosis could help us understand intersubject variations in treatment response. In this review, we compiled pharmacogenomic data on antituberculous drugs that were available from different settings that would give a better insight into the role of pharmacogenomics in the treatment of tuberculosis, thereby enhancing the efficacy and limiting the toxicity of existing antituberculosis medications. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 181 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| South Africa | 2 | 1% |
| Finland | 1 | <1% |
| India | 1 | <1% |
| Egypt | 1 | <1% |
| Unknown | 176 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 32 | 18% |
| Researcher | 23 | 13% |
| Student > Bachelor | 21 | 12% |
| Student > Ph. D. Student | 15 | 8% |
| Student > Postgraduate | 9 | 5% |
| Other | 30 | 17% |
| Unknown | 51 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 27 | 15% |
| Agricultural and Biological Sciences | 22 | 12% |
| Biochemistry, Genetics and Molecular Biology | 21 | 12% |
| Immunology and Microbiology | 9 | 5% |
| Other | 14 | 8% |
| Unknown | 52 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2013.
All research outputs
#17,562,823
of 25,748,735 outputs
Outputs from Pharmacogenomics and Personalized Medicine
#1
of 1 outputs
Outputs of similar age
#126,077
of 188,906 outputs
Outputs of similar age from Pharmacogenomics and Personalized Medicine
#1
of 1 outputs
Altmetric has tracked 25,748,735 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1 research outputs from this source. They receive a mean Attention Score of 1.0. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,906 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them